RMC-9805 (Not yet branded)
Other Medications
Description
RMC-9805 is a RAS(ON) inhibitor specifically designed to target KRAS G12D-mutated solid tumors, including colorectal cancer. This compound represents a novel approach to directly inhibiting mutant KRAS proteins in their active GTP-bound state. RMC-9805 is being developed for patients with KRAS G12D mutations, which occur in approximately 12-15% of colorectal cancers and have historically been considered "undruggable" targets.
Mechanism of Action
RMC-9805 functions as a RAS(ON) inhibitor that directly binds to and inhibits the KRAS G12D mutant protein in its active, GTP-bound conformation. This mechanism differs from traditional KRAS G12C inhibitors by targeting the protein while it is in the "on" state rather than the inactive GDP-bound state. By blocking active KRAS G12D signaling, the drug disrupts downstream oncogenic pathways including RAF-MEK-ERK and PI3K-AKT cascades that drive tumor growth and survival.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.